Company intelligence
Chardan
Where disruption banks. ™
About Chardan
Chardan is an independent global investment bank specializing in SPACs, healthcare, and disruptive innovation spanning all sectors. Our range of services include capital raising, merger and acquisition advisory, strategic advisory, equity research, corporate access and institutional trading. Headquartered in New York City, Chardan is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: FINRA, SIPC, and NASDAQ. Disclaimer: Information posted on this Web site is believed to be reliable at the time of posting; Chardan Capital Markets, LLC and its affiliates cannot, however, guarantee the accuracy or completeness of such information or make any warranties with regard to the results to be obtained from its use. Information on this Web site is not intended to provide financial, legal, accounting or tax advice and should not be relied upon in that regard. Chardan Capital Markets, LLC and its affiliates are not responsible in any manner for direct, indirect, special or consequential damages howsoever caused, arising out of the use of this Web site or any of its content.
Verified activity
Signals from Chardan
7 published signals
Research & Knowledge
Chardan Senior Research Analyst Keay Nakae initiated coverage on Vyome Holdings, Inc. (NASDAQ: HIND) with a Buy rating and $3.50 price target on the commercial potential of the Company's lead candidate VT-1953 in treating malodor symptoms in malignant fungating wounds (MFW), with additional upside from VT-1908 in non-infectious uveitis, and longer-term potential upside in immune-inflammatory indications from recently licensed selective JAK inhibitors.
Reported by Chardan
People
Chardan is hiring a new Equity Research Associate for Digital Assets and Infrastructure in New York City Metropolitan Area.
Reported by Chardan
Research & Knowledge
Chardan Research highlighted CRISPR Therapeutics reporting Phase 1a data for CTX310, an in vivo CRISPR-Cas9 therapy targeting ANGPTL3.
Reported by Chardan
Research & Knowledge
Chardan Research highlighted Arrowhead Pharmaceuticals presenting 12-month Phase 3 SHASTA-3/4 data at the European Society of Cardiology (ESC) Congress 2026 showing plozasiran significantly reduced triglyceride levels and acute pancreatitis events in patients with severe hypertriglyceridemia.
Reported by Chardan
Research & Knowledge
Chardan Research highlighted Alnylam Pharmaceuticals and Ionis Pharmaceuticals presenting contrasting findings at the European Society of Cardiology (ESC) on transthyretin (TTR) amyloidosis therapies.
Reported by Chardan
Research & Knowledge
Chardan Research highlighted REGENXBIO announcing the FDA placed a clinical hold on RGX-121 for MPS II following identification of asymptomatic spinal nodules or cystic masses in five trial participants.
Reported by Chardan
Research & Knowledge
Chardan published its weekly DAT report highlighting market trends, company-specific updates, and emerging opportunities in Bitcoin, Ethereum, HYPE, and Solana.
Reported by Chardan